In 3D dermal models, SkinNexus Collag3n supported collagen homeostasis across the entire spectrum: +48 % for collagen I, +82 % for collagen III, and +71 % for collagen V. Clinical trials conducted in women aged 53–70 showed improvements in sagging and the appearance of wrinkles after four weeks, outperforming a collagen benchmark used at a concentration ten times higher.
Screening of more than 2,000 fragments using AI
BASF and Bota combined AI, synthetic biology, skin science, and bioproduction to screen more than 2,000 collagen fragments. The evaluation of the candidates took place in parallel with an industrial feasibility assessment. This short cycle linked discovery and production. «SkinNexus Collag3n reflects our commitment to high performance grounded in science.". Bota Biosciences »has been the partner of choice for combining high efficiency with industrial-scale production", says Lucilene Veira Nunes, head of global business management at BASF Beauty Care Solutions.
Recombinant collagen III, 100 %, identical to human collagen
The ingredient is a vegan, recombinant collagen III fragment produced through yeast fermentation, with a 100 % sequence identical to that found in humans. It is intended for the personal care market and is marketed by BASF. «This collaboration demonstrates that Physical IA applied to bioproduction can transform cutting-edge science into commercial, sustainable, and high-performance ingredients. Together with BASF, we are setting new standards for bio-identical active ingredients in cosmetics.», says Cheryl Cui, founder and CEO of Bota Biosciences.
The ingredient made its global debut at in-cosmetics Global in April 2026. BASF and Bota are continuing their collaboration on bio-based innovations for the global market.
